The Medically 1 Associated Science and Technology (MAST) program at Cedars-Sinai is dedicated
to the development of novel drugs and devices to diagnose and treat patients.
The microbiome is the cluster of bacteria and flora that live within us, and can influence our health and well-being. We are determined to study the gut microbiome by combining laboratory research with clinical studies. Learn more about our latest research by clicking below.
At MAST, patients are at the center of our work, which gives us a unique perspective as we innovate. Having direct interactions with patients drives our curiosity toward clinically meaningful questions and allows us to move quickly toward identifiable solutions. The MAST team brings expertise in working with the microbiome in both basic and clinical aspects, along with a track record of navigating the U.S. Food and Drug Administration (FDA) approval process and post-FDA approval work.